Division Bench of Delhi High Court restrains Glenmark from manufacturing Anti-Diabetes drugs over patent infringement claimed by US Company

A Division Bench of the Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing, marketing or selling its anti-diabetes drugs Zita and Zita-Met, reasoning that it has prima facie infringed the patent of US drug major Merck Sharp and Dohme (MSD). Both sides were represented by a battery of senior advocates including Kapil Sibbal, A.M.Singhvi...